Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGMN | Q99538 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 5/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29744988 | 1.00 | LGMN (0.51) | LGMNALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL3922530 | 0.93 | ALDH1A1 (0.50) | LGMNALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL24196340 | 0.91 | ALDH1A1 (0.50) | LGMNALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL518889 | 0.91 | ALDH1A1 (0.50) | LGMNALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL29300840 | 0.86 | ALDH1A1 (0.47) | LGMNALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL7550699 | 0.86 | MAPT (0.54) | LGMNALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL23759790 | 0.86 | ALDH1A1 (0.61) | LGMNALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL10994974 | 0.86 | ALDH1A1 (0.47) | LGMNALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL21262291 | 0.86 | MAPT (0.54) | LGMNALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL2363906 | 0.84 | ALDH1A1 (0.46) | LGMNALDH1A1KDM4ELMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220380319-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL R&D INVEST S A (PT) | 2022-12-01 | — | — | US | disclosed |
| EP-4031532-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | Bial-R&D Investments, S.A. (PT) | 2022-07-27 | — | — | EP | disclosed |
| CN-114787136-A | Substituted benzimidazole carboxamides and their use in the treatment of medical disorders | 比亚尔R&D投资股份公司 | 2022-07-22 | — | — | CN | disclosed |
| US-20220002313-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | UNIVERSITY HEALTH NETWORK (CA) | 2022-01-06 | — | — | US | disclosed |
| US-20220002313-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | UNIVERSITY HEALTH NETWORK (CA) | 2022-01-06 | — | — | US | disclosed |
| CN-113214287-A | HPK1 inhibitors and methods of use thereof | 大学健康网络 | 2021-08-06 | — | — | CN | disclosed |
| US-11059832-B2 | HPK1 inhibitors and methods of using same | UNIVERSITY HEALTH NETWORK (CA) | 2021-07-13 | — | — | US | disclosed |
| US-11059832-B2 | HPK1 inhibitors and methods of using same | UNIVERSITY HEALTH NETWORK (CA) | 2021-07-13 | — | — | US | disclosed |
| CN-107922431-B | HPK1 inhibitors and methods of use thereof | 大学健康网络 | 2021-06-04 | — | — | CN | disclosed |
| WO-2021055591-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL-BioTech Investments, Inc. (US) | 2021-03-25 | — | — | WO | disclosed |
| CN-101203518-B | Fluorene derivative, composition containing the same and use thereof | AVENTIS PHARMA SA | 2013-07-24 | — | — | CN | disclosed |
| EP-1888579-B1 | NOVEL FLUORENE DERIVATIVES, COMPOSITION CONTAINING SAID DERIVATIVES AND THE USE THEREOF | AVENTIS PHARMA SA (FR) | 2011-08-03 | — | — | EP | disclosed |
| US-7674795-B2 | Fluorene derivatives, composition containing said derivatives and the use thereof | AVENTIS PHARMA SA (FR) | 2010-03-09 | — | — | US | disclosed |
| US-20090197866-A1 | PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2009-08-06 | — | — | US | disclosed |
| EP-2041119-A1 | PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | Aventis Pharma S.A. (FR) | 2009-04-01 | — | — | EP | disclosed |
| US-20080153837-A1 | Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof | AVENTIS PHARMA S.A. (FR) | 2008-06-26 | — | — | US | disclosed |
| CN-101203518-A | Novel fluorene derivatives, compositions containing same and uses thereof | AVENTIS PHARMA SA (FR) | 2008-06-18 | — | — | CN | disclosed |
| EP-1888579-A2 | NOVEL FLUORENE DERIVATIVES, COMPOSITION CONTAINING SAID DERIVATIVES AND THE USE THEREOF | Aventis Pharma S.A. (FR) | 2008-02-20 | — | — | EP | disclosed |
| WO-2008003857-A1 | PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2008-01-10 | — | — | WO | disclosed |
| WO-2006123061-A2 | FLUORENE DERIVATIVES, COMPOSITION CONTAINING SAID DERIVATIVES AND THE USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059832-B2 | HPK1 inhibitors and methods of using same | PDXK, PDK3, PDK2 | LGMN 3863/4885ALDH1A1 2442/4885KDM4E 941/4885 |
| US-20090197866-A1 | PYRAZOLYLBENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND USE THEREOF | RB1, CCNI, CDK2 | LGMN 4583/4885ALDH1A1 874/4885KDM4E 1847/4885 |
| US-20220002313-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | PDXK, PDK3, PDK2 | LGMN 3774/4885ALDH1A1 2458/4885KDM4E 930/4885 |
| US-20220380319-A1 | SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GAA, GBA1, CLN6 | LGMN 737/4885ALDH1A1 1096/4885KDM4E 637/4885 |
| US-20080153837-A1 | Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof | HSP90B1, HSP90AB1, HSP90AA1 | LGMN 4483/4885ALDH1A1 3050/4885KDM4E 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.